Effectiveness and safety of dexamphetamine sulfate (Attentin®) in the routine treatment of children and adolescents with ADHD: results from a 12-month non-interventional study
References
- Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics 2015;135(4):e994-1001.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC, American Psychiatric Association; 2013.
- World Health Organization. International Classification of Diseases (ICD-10). 1992.
- AWMF. Langfassung der interdisziplinären evidenz- und konsensbasierten (S3) Leitlinie “Aufmerksamkeitsdefizit- / Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter”. Registernummer 028 - 045. [Long version of the interdisciplinary evidence and consensus-based (S3) guideline “Attention Deficit / Hyperactivity Disorder (ADHD) in children, adolescents and adults]; 2018 [Available from: https://www.awmf.org/leitlinien/detail/ll/028-045.html
- Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of Attention-Deficit/Hyperactivity Disorder in children and adolescents. Pediatrics 2019;144(4):e20192528.
- CADDRA. Canadian ADHD Practice Guidelines; Fourth Edition. Toronto ON: CADDRA; 2018.
- National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE guideline [NG87]. 2018 [Available from: nice.org.uk/guidance/ng87].
- Pliszka SR. Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action. Neuropsychol Rev 2007;17(1):61-72.
- Punja S, Shamseer L, Hartling L, Urichuk L, Vandermeer B, Nikles J, et al. Amphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Cochrane Database Syst Rev 2016;2:CD009996.
- Coghill DR, Banaschewski T, Soutullo C, Cottingham MG, Zuddas A. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2017;26(11):1283-307.
- Boland H, DiSalvo M, Fried R, Woodworth KY, Wilens T, Faraone SV, et al. A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. J Psychiatr Res 2020;123:21-30.
- Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010;19(4):353-64.
- Faraone SV. The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev 2018;87:255-70.
- Easton N, Steward C, Marshall F, Fone K, Marsden C. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology 2007;52(2):405-14.
- Riddle EL, Hanson GR, Fleckenstein AE. Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2. Eur J Pharmacol 2007;571(1):25-8.
- Robinson JB. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl. Biochem Pharmacol 1985;34(23):4105-8.
- Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 1995;15(5 Pt 2):4102-8.
- Steingard R, Taskiran S, Connor DF, Markowitz JS, Stein MA. New formulations of stimulants: an update for clinicians. J Child Adolesc Psychopharmacol 2019;29(5):324-39.
- MEDICE Arzneimittel Pütter GmbH & Co KG. Attentin 5/10/20 mg SmPC. 06/2020.
- Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res 1991;36(2):141-55.
- Sharp WS, Walter JM, Marsh WL, Ritchie GF, Hamburger SD, Castellanos FX. ADHD in girls: clinical comparability of a research sample. J Am Acad Child Adolesc Psychiatry 1999;38(1):40-7.
- Elia J, Welsh PA, Gullotta CS, Rapoport JL. Classroom academic performance: improvement with both methylphenidate and dextroamphetamine in ADHD boys. J Child Psychol Psychiatry 1993;34(5):785-804.
- Pelham WE, Jr., Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, et al. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics 1990;86(2):226-37.
- James RS, Sharp WS, Bastain TM, Lee PP, Walter JM, Czarnolewski M, et al. Double-blind, placebo-controlled study of single-dose amphetamine formulations in ADHD. J Am Acad Child Adolesc Psychiatry 2001;40(11):1268-76.
- Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B, et al. Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997;54(9):857-64.
- Ramtvedt BE, Roinas E, Aabech HS, Sundet KS. Clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials. J Child Adolesc Psychopharmacol 2013;23(9):597-604.
- Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018;5(9):727-38.
- Hodgkins P, Shaw M, Coghill D, Hechtman L. Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry 2012;21(9):477-92.
- Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002;41(2 Suppl):26S-49S.
- Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 2013;54(3):227-46.
- Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther 2018;35(11):1763-1774.
- Zhang S, Faries DE, Vowles M, Michelson D. ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument. Int J Methods Psychiatr Res 2005;14(4):186-201.
- R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/; 2020.
- Wickham H, Miller E. Import and Export 'SPSS', 'Stata' and 'SAS' Files. R package version 2.3.1., Package ‘haven’ https://CRAN.R-project.org/package=haven; 2020.
- McLeod M, Laubscher T, Regier L, Jensen B. Taking the stress out of individualizing ADHD drug therapy. Can Fam Physician 2009;55(9):895-8.
- Greydanus DE, Sloane MA, Rappley MD. Psychopharmacology of ADHD in adolescents. Adolesc Med 2002;13(3):599-624.
- Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009;48(3):240-8.
- Brown GL, Hunt RD, Ebert MH, Bunney WE, Jr., Kopin IJ. Plasma levels of d-amphetamine in hyperactive children. Serial behavior and motor responses. Psychopharmacology (Berl) 1979;62(2):133-40.
- Huss M, Duhan P, Gandhi P, Chen CW, Spannhuth C, Kumar V. Methylphenidate dose optimization for ADHD treatment: review of safety, efficacy, and clinical necessity. Neuropsychiatr Dis Treat 2017;13:1741-51.
- Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47(9):994-1009.
- Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, et al. Cardiovascular effects of stimulant and non-stimulant medication for children and adolescents with ADHD: a systematic review and meta-analysis of trials of methylphenidate, amphetamines and atomoxetine. CNS drugs 2017;31(3):199-215.
- Cortese S. Pharmacologic treatment of Attention Deficit– Hyperactivity Disorder. N Engl J Med 2020;383(11):1050-6.
- Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. Eur Neuropsychopharmacol 2013;23(6):534-41.
- Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry 2011;50(10):978-90.
- Liu H, Feng W, Zhang D. Association of ADHD medications with the risk of cardiovascular diseases: a meta-analysis. Eur Child Adolesc Psychiatry 2019;28(10):1283-93.
- Cortese S, Coghill D. Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward. Evid Based Ment Health 2018;21(4):173-6.
DOI: https://doi.org/10.21307/sjcapp-2021-009 | Journal eISSN: 2245-8875
Language: English
Page range: 73 - 86
Published on: Apr 23, 2021
Published by: Psychiatric Research Unit
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
Related subjects:
© 2021 Henrik Uebel-von Sandersleben, Oliver Dangel, Roland Fischer, Michaela Ruhmann, Michael Huss, published by Psychiatric Research Unit
This work is licensed under the Creative Commons Attribution 4.0 License.